Aducanumab and the “post-amyloid” era of Alzheimer research?

Erik S. Musiek; David A. Bennett

doi:10.1016/j.neuron.2021.09.007

Aducanumab and the “post-amyloid” era of Alzheimer research?

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	3045-3047
Number of pages	3
Journal	Neuron
Volume	109
Issue number	19
DOIs	https://doi.org/10.1016/j.neuron.2021.09.007
State	Published - Oct 6 2021

Access to Document

10.1016/j.neuron.2021.09.007

Cite this

@article{6c66c7c56ee24d6e9f1138e4ea908b59,

title = "Aducanumab and the “post-amyloid” era of Alzheimer research?",

author = "Musiek, {Erik S.} and Bennett, {David A.}",

note = "Funding Information: Dr. Musiek has provided consultation and has received research funding from Eisai Pharmaceuticals, the co-developer of aducanumab and developer of lecanemab. This interaction with Eisai is related to basic sleep research and is unrelated to aducanumab, lecanemab, or any other amyloid antibodies. No personal compensation was provided. Dr. Bennett has consulted for Takeda, Abbvie, Origent, and Vigorous Minds. He has received research funding from Biogen, the developer of aducanumab, for data analysis of data generated from his own group, and from Neurovision.",

year = "2021",

month = oct,

day = "6",

doi = "10.1016/j.neuron.2021.09.007",

language = "English",

volume = "109",

pages = "3045--3047",

journal = "Neuron",